Comments on: What is Fair for Drug Exclusivity? http://blog.pharmtech.com/2009/06/12/what-is-fair-for-drug-patent-exclusivity/ The blog of Pharmaceutical Technology magazine Thu, 09 May 2013 23:30:55 -0400 http://wordpress.org/?v=2.8.4 hourly 1 By: CMCguy http://blog.pharmtech.com/2009/06/12/what-is-fair-for-drug-patent-exclusivity/comment-page-1/#comment-14732 CMCguy Mon, 15 Jun 2009 19:48:35 +0000 http://blog.pharmtech.com/?p=1415#comment-14732 The post well states the current system may be potentially harmful to "innovators" (if assume Patent exclusivity too short) and that there are many ways to view competition in drugs that lead to new drugs. Patent terms do provide a framework for sustaining profitability however an overly long period could negatively skew how companies deal with future directions so there must be a balance. The unpredictable factors for Clinical Development and Review Process make it difficult to set precise parameters but any exclusivity period should begin after Approval. There must be substantial "reward" or no one would undertake the "risks" of drug discovery & development (unfortunately many companies have either "appeared to rest on their laurels" or "emphasized limited project areas" so there has been lack of innovation of late). The rewards of today (profits) pay for innovations of tomorrow and many Generics tap into the reward portion without (much) reinvestment into the risk side of the equation. . The post well states the current system may be potentially harmful to “innovators” (if assume Patent exclusivity too short) and that there are many ways to view competition in drugs that lead to new drugs. Patent terms do provide a framework for sustaining profitability however an overly long period could negatively skew how companies deal with future directions so there must be a balance. The unpredictable factors for Clinical Development and Review Process make it difficult to set precise parameters but any exclusivity period should begin after Approval.

There must be substantial “reward” or no one would undertake the “risks” of drug discovery & development (unfortunately many companies have either “appeared to rest on their laurels” or “emphasized limited project areas” so there has been lack of innovation of late). The rewards of today (profits) pay for innovations of tomorrow and many Generics tap into the reward portion without (much) reinvestment into the risk side of the equation. .

]]> By: Josh K http://blog.pharmtech.com/2009/06/12/what-is-fair-for-drug-patent-exclusivity/comment-page-1/#comment-14603 Josh K Sat, 13 Jun 2009 05:54:47 +0000 http://blog.pharmtech.com/?p=1415#comment-14603 There has to be a concern that proposed modifications to the system could reduce patent rights and ultimately impede long term innovation. As the author points out, there are two sides of the argument but policy makers should focus on the long term effects of any changes. For more information, see http://www.generalpatent.com/inventor-resources/basics-intellectual-property There has to be a concern that proposed modifications to the system could reduce patent rights and ultimately impede long term innovation. As the author points out, there are two sides of the argument but policy makers should focus on the long term effects of any changes.

For more information, see http://www.generalpatent.com/inventor-resources/basics-intellectual-property

]]>